The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TP53 mutations in EGFR mt+ NSCLC IV as a predictive factor for ORR, PFS, and OS irrespective of T790M.
 
Julia Roeper
Honoraria - Boehringer Ingelheim; Roche
 
Anne Christina Lueers
No Relationships to Disclose
 
Markus Falk
Honoraria - AstraZeneca; Boehringer Ingelheim; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Pfizer
 
Markus Tiemann
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Novartis
 
Fabian Otto-Sobotka
No Relationships to Disclose
 
Frank Griesinger
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; MSD; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MSD; Novartis; Pfizer; Roche/Genentech; Takeda
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)